drugset
drugset / Trial / NCT05420220

Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

NCT05420220 ↗

Phase 2 Completed 95 enrolled Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, multi-center, Phase 2 study in subjects with treatment-naïve locally advanced (unresectable and unable to receive radical chemoradiotherapy) or metastatic PD-L1-positive non-small cell lung cancer (NSCLC) who have received systemic therapy.

Timeline

Start
2022-07-26
Primary completion
2024-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 3 mg Oral
Subject Axitinib Small molecule 5 mg Oral
Subject ERFONRILIMAB Monoclonal antibody 5 mg/kg Intravenous

Indications

non-small cell lung carcinoma